IBIO
iBio, Inc. Common StockNASDAQ
Healthcare • Biotechnology
Factor tilt: Micro-Cap Value
$0.74+1.16%
Close Nov 6, 2026
- Market cap
- $76.86M
- 1 month
- -19.7%
- 3 months
- -47.2%
- 1 year
- -48.7%
- 52-week range
- $0.71$3.07
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.08Quarter to Sep 30, 2026 · 7 analysts · revenue $16.67K · -0.9% in 30d
- Short interest
- 7.2% of float3.7M shares · settled Oct 15, 2026 · -11.2% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $100K
- Net income
- -$33.04M
- Free cash flow
- -$23.8M
- Book value
- $85.71M
- Total debt
- $2.2M
- P/E
- —
- Price / sales
- 768.6×
- Price / book
- 0.9×
- FCF yield
- -31.0%
- Net margin
- -33,044.0%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
Read more
The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies. In addition, the company is developing, an antibody therapeutics to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2"expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
- Website
- ibioinc.com
- Headquarters
- San Diego, CA, United States
- Employees
- 23
- Listed
- Aug 19, 2008
- Fiscal year ends
- June
Company profile from EODHD, stored Nov 6, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 28, 2026 | — | — | — | -$16.4M | -$10.6M |
| Mar 2026filed May 12, 2026 | — | — | — | -$5.9M | -$7.7M |
| Dec 2025filed Feb 10, 2026 | — | — | — | -$6.9M | -$9.0M |
| Sep 2025filed Nov 12, 2025 | $100.0K | — | -189.0% | -$6.0M | -$5.7M |
| Jun 2025filed Sep 5, 2025 | $200.0K | +14.3% | 100.0% | -$5.2M | -$5.2M |
| Mar 2025filed May 2, 2025 | — | — | — | -$4.9M | -$4.9M |
| Dec 2024filed Feb 10, 2025 | $200.0K | — | 100.0% | -$4.4M | -$4.4M |
| Sep 2024filed Nov 12, 2024 | — | — | — | -$4.1M | -$4.0M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 28, 2026 | $100.0K | -75.0% | — | -$35.1M | -$33.0M |
| Jun 2025filed Sep 5, 2025 | $400.0K | +77.8% | 100.0% | -$18.6M | -$18.4M |
| Jun 2024filed Sep 20, 2024 | $225.0K | +350.0% | — | -$16.6M | -$24.9M |
| Jun 2023filed Sep 27, 2023 | $50.0K | -97.3% | — | -$29.3M | -$29.3M |
| Jun 2022filed Oct 11, 2022 | $1.9M | -20.5% | -101.2% | -$29.7M | -$50.4M |
| Jun 2021filed Sep 28, 2021 | $2.4M | +44.7% | 38.3% | -$31.1M | -$23.2M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched IBIO. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
3,732,883 shares short
-469,536 shares (-11.2%) vs Sep 30, 2026
7.2% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
4,202,419 shares short
-734,498 shares (-14.9%) vs Sep 15, 2026
8.1% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
4,936,917 shares short
-267,558 shares (-5.1%) vs Aug 31, 2026
10.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
5,204,475 shares short
+176,601 shares (+3.5%) vs Aug 14, 2026
11.4% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
5,027,874 shares short
-77,839 shares (-1.5%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
5,105,713 shares short
-278,766 shares (-5.2%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind IBIO’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 20 · reverse split
Effective Nov 29, 2023
Each 20 pre-split shares become 1 post-split share.
Source: EODHD
1 for 25 · reverse split
Effective Oct 10, 2022
Each 25 pre-split shares become 1 post-split share.
Source: EODHD
1 for 10 · reverse split
Effective Jun 11, 2018
Each 10 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if IBIO is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
17 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
55 filers reported a long position in IBIO for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
70.2%
of the 34.7M shares 13-F filers reported
Moves vs Q1 2026
5 added0 trimmed
4 new · 1 unchanged
Net shares held
+64.6%
across the 6 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | Affinity Asset Advisors, LLC | $7M · 4M shares | 4M | +29% |
| 2 | Cormorant Asset Management, LP | $6.2M · 3.6M shares | 3.6M | New |
| 3 | SILVERARC CAPITAL MANAGEMENT, LLC | $6.2M · 3.5M shares | 3.5M | +1,457.7% |
| 4 | Vestal Point Capital, LP | $4.6M · 2.6M shares | 2.6M | New |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $3.7M · 2.1M shares | 2.1M | +92.8% |
| 6 | Frazier Life Sciences Management, L.P. | $3.4M · 2M shares | 2M | Unchanged |
| 7 | Ensign Peak Advisors, Inc | $3.2M · 1.8M shares | 1.8M | New |
| 8 | Woodline Partners LP | $3.1M · 1.8M shares | 1.8M | New |
| 9 | MILLENNIUM MANAGEMENT LLC | $2.9M · 1.7M shares | 1.7M | +6.6% |
| 10 | CITADEL ADVISORS LLC | $2.4M · 1.4M shares | 1.4M | +44.7% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of IBIO file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 14, 2026 | Coastlands Capital LP13G · passive | 9.72% |
| Aug 14, 2026 | Cormorant Asset Management, LP13G · passive · amended | 9.99% |
| Aug 14, 2026 | Lynx1 Capital Management LP13G · passive | 5.4% |
| Aug 14, 2026 | Vestal Point Capital, LP13G · passive · amended | 7.9% |
| Aug 13, 2026 | Affinity Asset Advisors, LLC13G · passive · amended | 9.99% |
| May 15, 2026 | Logos Global Management LP13G · passive · amended | 0%under 5% |
| May 15, 2026 | EcoR1 Capital, LLC13G · passive · amended | 4.6%under 5% |
| May 15, 2026 | Point72 Asset Management, L.P.13G · passive · amended | 0%under 5% |
| May 15, 2026 | Sirenia Capital Management LP13G · passive | 9.9% |
| May 12, 2026 | Frazier Life Sciences Public Fund LP13G · passive · amended | 5.7% |
Get the Full Analysis for IBIO
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.